Keros Therapeutics, Inc. Common Stock (KROS) Stock
NASDAQ · KROS
11.10
Fundamentals
Market cap
$230.39M
Price / Earnings ratio
-2.8x
Price / Sales ratio
15.3x
Price / Book ratio
0.9x
Return on assets
-16.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
NeutralKROSSeptember 2, 2026
Zacks Investment ResearchNeutral
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
KROS

Zacks Investment Research
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
NeutralKROSAugust 24, 2026
Zacks Investment ResearchNeutral
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
KROS

Zacks Investment Research
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
NeutralKROSAugust 24, 2026
Zacks Investment ResearchNeutral
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
KROS

Zacks Investment Research
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
NeutralKROSAugust 4, 2026
Zacks Investment ResearchNeutral
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
KROS
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
293M193M97M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
406M268M134M0
Revenue to Profit
2025$244.1M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$87.0M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Zacks Investment Research
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
NeutralKROSSeptember 2, 2026
Zacks Investment ResearchNeutral
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
KROS

Zacks Investment Research
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
NeutralKROSAugust 24, 2026
Zacks Investment ResearchNeutral
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
KROS

Zacks Investment Research
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
NeutralKROSAugust 24, 2026
Zacks Investment ResearchNeutral
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
KROS

Zacks Investment Research
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
NeutralKROSAugust 4, 2026
Zacks Investment ResearchNeutral
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
KROS

Zacks Investment Research
New Strong Sell Stocks for July 30th
NeutralKROSJuly 30, 2026
Zacks Investment ResearchNeutral
New Strong Sell Stocks for July 30th
KROS

Zacks Investment Research
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
NeutralKROSMay 22, 2026
Zacks Investment ResearchNeutral
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
KROS

Zacks Investment Research
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
NeutralKROSMay 22, 2026
Zacks Investment ResearchNeutral
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
KROS

Zacks Investment Research
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
NeutralKROSMay 22, 2026
Zacks Investment ResearchNeutral
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
KROS

Zacks Investment Research
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
NeutralKROSMay 15, 2026
Zacks Investment ResearchNeutral
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
KROS

Zacks Investment Research
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
NeutralKROSMay 14, 2026
Zacks Investment ResearchNeutral
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
KROS
About Keros Therapeutics, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees92
CEODr. Jasbir S. Seehra Ph.D.
IPO DateApr 8, 2020
HeadquartersLexington, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, CEO & Director | 1956 |
| Ms. Esther Cho J.D. | Chief Legal Officer & Secretary | 1989 |
| Ms. Annita Tanini | VP, Corporate Controller and Interim Principal Financial & Accounting Officer | 1971 |
| Justin Frantz | Head of Investor Relations | — |
| Dr. Lorena Lerner Ph.D. | Chief Scientific Officer | 1972 |
Fundamentals
Valuation
Market cap$230.39M
Price-to-sales ratio15.25
Price-to-book value0.87
Price-earnings ratio-2.80
Return on Equity-17.00%
Return on Sales-272.00%
Return on Assets-16.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-3.22
Income Statement
Average volume183,532
EBITDA$-86.28M
1 year high (52w)$22.55
1 year low (52w)$9.69
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$18.00
Est return
51.64%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -3.8 | +4.5 | +30.3 | +10.3 | ||||||||
| 2022 | -21.9 | +8.8 | +1.6 | -10.8 | -39.2 | -16.1 | +14.2 | +18.7 | +2.7 | +27.6 | -1.7 | -4.1 |
| 2023 | +27.4 | -8.7 | -22.0 | +3.0 | +3.9 | -15.9 | +5.0 | -14.6 | -12.0 | -7.4 | +6.1 | +29.8 |
| 2024 | +28.4 | +18.0 | -3.8 | -15.7 | -18.8 | -6.1 | +14.6 | -9.9 | +21.5 | -2.9 | -3.7 | -72.1 |
| 2025 | -28.4 | -0.4 | -8.2 | +51.2 | -2.9 | -8.9 | +7.3 | +6.2 | +0.6 | -0.4 | +14.8 | +18.5 |
| 2026 | -3.4 | -22.9 | -20.6 | -4.9 | -2.1 | -1.8 | -7.4 | +9.6 | +5.0 |



